Osteoporosis Drug Use in Chronic Kidney Disease – Medscape

MedscapeOsteoporosis Drug Use in Chronic Kidney DiseaseMedscapeOsteoporosis drugs including oral bisphosphonates show efficacy and safety in the treatment of bone loss in patients with chronic kidney disease (CKD) in several observational studies. However, caution is still urged, particularly with oral … Source:: DXA Feed       

Desonumab Discontinuation for Osteoporosis: What Are the Risks? – Rheumatology Advisor (registration)

Rheumatology Advisor (registration)Desonumab Discontinuation for Osteoporosis: What Are the Risks?Rheumatology Advisor (registration)Discontinuing desonumab therapy in osteoporosis may increase the risk of vertebral fractures, according to a systematic literature review recently published in Bone.1 In addition, measures and treatments aimed at curbing treatment-associated bone loss … Source:: Osteoporosis Feed       

BMD of Femoral Neck Declines Twice as Fast in HIV-Infected Women – Endocrinology Advisor

Endocrinology AdvisorBMD of Femoral Neck Declines Twice as Fast in HIV-Infected WomenEndocrinology AdvisorHIV-infected men (N=1759) and women (N=839) on long-term antiretroviral therapy (ART) in the Modena Metabolic Clinic underwent dual-electron X-ray absorptiometry (DXA) scans every 6 to 12 months for up to 10 years. To determine factors associated … Source:: DXA Feed       

Romosozumab versus teriparatide – Nature.com

Romosozumab versus teriparatideNature.comThe effect of two bone-forming agents — the anti-sclerostin antibody romosozumab and the recombinant PTH teriparatide — were compared in an open-label, randomized phase III study involving 436 women with postmenopausal osteoporosis who had been … Source:: Osteoporosis Feed       

Osteoporosis medications may improve bone health in men receiving androgen deprivation therapy for prostate cancer – 2 Minute Medicine

2 Minute MedicineOsteoporosis medications may improve bone health in men receiving androgen deprivation therapy for prostate cancer2 Minute MedicineConsidering that most men with prostate cancer are elderly and already at risk of osteoporosis, the risks of ADT therapy are even more important. This systematic review sought to evaluate drug, supplement, and lifestyle interventions for their … Continue reading

After RYGB, BMD decreases tied to bone marrow fat increases in women – Healio

After RYGB, BMD decreases tied to bone marrow fat increases in womenHealioBMD was measured by DXA and quantitative CT and vertebral marrow fat content was measured by magnetic resonance spectroscopy before and 6 months after RYGB. Participants with type 2 diabetes had lower preoperative weight and BMI compared with … Source:: DXA Feed       

Osteoporosis medications improve bone health in men being treated for prostate cancer – EurekAlert (press release)

Osteoporosis medications improve bone health in men being treated for prostate cancerEurekAlert (press release)Both bisphosphonates and denosumab improve bone mineral density (BMD) in men with nonmetastatic prostate cancer who are receiving androgen deprivation therapy (ADT). The results from a systematic review and meta-analysis are published in Annals of … Source:: Osteoporosis Feed       

Managing Osteoporosis With Type 2 Diabetes: An Expert Opinion – Endocrinology Advisor

Managing Osteoporosis With Type 2 Diabetes: An Expert OpinionEndocrinology AdvisorThe Journal of Clinical Endocrinology and Metabolism recently published a systematic review of scientific evidence regarding the management of type 2 diabetes and osteoporosis. Endocrinology Advisor spoke with one of the authors, Anastasia D. Dede, MD, … Source:: Osteoporosis Feed       

NICE lowers risk threshold for prescribing bisphosphonates to 1% – Pulse

PulseNICE lowers risk threshold for prescribing bisphosphonates to 1%PulseGPs should consider patients at lower risks of osteoporotic fracture for bisphosphonates treatment as the drugs are ‘clinically effective’ at this level, says a new NICE appraisal. New advice from the NICE technology appraisal on bisphosphonates for … Source:: DXA Feed       

Neridronic acid safe, effective in children with osteogenesis imperfecta – Healio

Neridronic acid safe, effective in children with osteogenesis imperfectaHealio“The positive effects of bisphosphonates on areal BMD (by DXA) at the spine and other skeletal sites are widely recognized. More controversial is the question of what clinically relevant benefit children with [osteogenesis imperfecta] may have from … Source:: DXA Feed       

In HIV, Greater BMD Decline for Immediate Versus Delayed ART – Doctors Lounge

In HIV, Greater BMD Decline for Immediate Versus Delayed ARTDoctors LoungeBaseline and follow-up DXA scans were available for 195 participants in the immediate group and 204 in the deferred group. The researchers found that, compared with deferred ART, immediate ART correlated with significantly greater BMD declines at the … Source:: DXA Feed       

Review highlights effective treatment options for managing patients with T2D and osteoporosis – News-Medical.net

Review highlights effective treatment options for managing patients with T2D and osteoporosisNews-Medical.netType 2 diabetes (T2D) and osteoporosis often coexist in patients, but managing both conditions can be a challenge. A comprehensive review published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism highlights the most effective …and more Source:: Osteoporosis Feed       

New class drug significantly reduces spine fracture risk in postmenopausal women with osteoporosis – EurekAlert (press release)

New class drug significantly reduces spine fracture risk in postmenopausal women with osteoporosisEurekAlert (press release)Madrid, Spain, 14 June 2017: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that, in postmenopausal women with osteoporosis, 12 months treatment with romosozumab …and more Source:: Osteoporosis Feed       

ACR Releases Guideline on prevention and treatment of glucocorticoid-induced osteoporosis – Medical Xpress

ACR Releases Guideline on prevention and treatment of glucocorticoid-induced osteoporosisMedical XpressThe American College of Rheumatology’s (ACR) updated clinical guideline for the prevention and treatment of glucocorticoid-induced osteoporosis is now available online. The guideline provides recommendations on assessing fracture risk and treatment for … Source:: Osteoporosis Feed       

Amgen Osteoporosis Drug Approval Plan Derailed Over Newly Found Heart Safety Risk Signal – TheStreet.com

TheStreet.comAmgen Osteoporosis Drug Approval Plan Derailed Over Newly Found Heart Safety Risk SignalTheStreet.com… the incidence of positively adjudicated cardiovascular serious adverse events as 12 months was 2.5% in the Evenity-treated patients compared to 1.9% in the group of patients treated with alendronate, a generic osteoporosis drug that served as the …Higher rate of heart problems … Continue reading

American Association of Clinical Endocrinologists and American College of Endocrinology Respond to American … – Business Wire (press release)

American Association of Clinical Endocrinologists and American College of Endocrinology Respond to American …Business Wire (press release)AACE/ACE guidelines recommend that after the initiating therapy, patients should be reassessed with dual energy absorptiometry (DXA) bone mineral density (BMD) every 1 to 2 years until findings are stable, with continued interval monitoring depending …and more Source:: DXA … Continue reading

ISCD Response to the American College of Physicians (ACP) Clinical Practice Guidelines for Treating Osteoporosis

Middletown, CT – The International Society for Clinical Densitometry, the world’s largest professional organization for bone densitometry, acknowledges and welcomes guidelines promoting best practices for quality bone density testing and treatment of osteoporosis. Our mission is to promote excellence in skeletal health assessment. We welcome the efforts of the American College of Physicians to update … Continue reading

FDA Approves Abaloparatide for Fragility Fracture in Postmenopausal Women With Osteoporosis – Endocrinology Advisor

FDA Approves Abaloparatide for Fragility Fracture in Postmenopausal Women With OsteoporosisEndocrinology AdvisorThe US Food and Drug Administration (FDA) has approved abaloparatide (Tymlos™; Radius Health) injection for postmenopausal women with osteoporosis at an increased risk of fracture, according to a press release.1. Abaloparatide approval was based on … Source:: Osteoporosis Feed       

AAFP Endorses ACP Guideline on Treating Osteoporosis – AAFP News

PulseAAFP Endorses ACP Guideline on Treating OsteoporosisAAFP NewsThe American College of Physicians (ACP) has issued a clinical practice guideline recommending that physicians treat women with osteoporosis using bisphosphonates or the biologic agent denosumab. The AAFP has endorsed the guideline, which also …The new NOGG guidelines for osteoporosisPulseall 3 news articles Source:: Osteoporosis Feed       

The new NOGG guidelines for osteoporosis – Pulse

PulseThe new NOGG guidelines for osteoporosisPulseThe advantage to using FRAX is that it links directly into the NOGG guidelines that give you advice as to treat without DXA, advise lifestyle advice or ask for bone densitometry. Since FRAX and QFracture yield different outputs (probability of fracture …and more Source:: Densitometry Feeds       

New ACP Guidelines on the Treatment of Osteoporosis – Medscape

MedscapeNew ACP Guidelines on the Treatment of OsteoporosisMedscapePhysicians should treat women with osteoporosis with one of the three main bisphosphonates or the biologic denosumab for a duration of 5 years, during which time monitoring of bone-mineral density (BMD) is not necessary, according to new clinical …Experts streamline guidelines for treating osteoporosisCNNACP issues guidelines to reduce … Continue reading

Newly discovered genetic mutation predisposes osteoporosis patients to femur fracture – Medical Xpress

Newly discovered genetic mutation predisposes osteoporosis patients to femur fractureMedical XpressResearchers at the Hospital del Mar Medical Research Institute (IMIM) and the University of Barcelona have uncovered a genetic mutation that makes bone vulnerable to bisphosphonates, drugs used to combat osteoporosis. Instead of strengthening bone …and more Source:: Osteoporosis Feed